An Oxygen‐Self‐Produced Nanoplatform Based on MnO₂ for Relieving Hypoxia

Abstract Manganese dioxide (MnO 2 ) nanoparticles are increasingly recognized for their potential in biomedical applications, particularly in the realm of hypoxic cancer therapy, due to their unique physicochemical characteristics. This investigation introduces a novel, template‐free synthesis strategy. The reducing groups inherent in bovine serum albumin (BSA) facilitate a redox reaction with potassium permanganate (KMnO 4 ), while the abundance of functional groups in BSA is instrumental in the formation of MnO 2 . The transmission electron microscopy (TEM) analysis has characterized the synthesized MnO 2 nanoparticles, termed BM NPs, as spherical particles with a mean diameter of 210 nm and zeta potential of −40.1 mV measured by dynamic light scattering (DLS). The Fourier transform infrared (FT‐IR) spectrum of BM NPs exhibits the characteristic peak of MnO 2 at 1113 cm −1 and 620 cm −1 . Furthermore, the elemental composition of BM NPs has been ascertained through energy‐dispersive X‐ray (EDX) elemental mapping analysis. Though concentration of BM NPs up to 200 μg/mL, the survival rate of 4T1 cells remained approximately 75 %. Given that BM NPs at a concentration of 100 μg/mL significantly alleviate cellular hypoxia, the high oxygen‐generating capacity of these nanoparticles is proved, suggesting their suitability as a drug delivery system, especially in the context of hypoxic tumor microenvironments.